Items Tagged with 'Perrigo'

Subscribe

Allegan-based Perrigo has begun what it claims is the first broad marketing and communications campaign to raise consumer awareness of, and confidence in, generic over-the-counter medications sold by major retailers under their own store brands. Read More

Perrigo Co. has begun shipments of guaifenesin tablets, the first generic equivalent to a Mucinex branded expectorant medicine. The tablets are going to Perrigo’s retail and wholesale customers, packaged and marketed under store and proprietary brands. Read More

Perrigo (Nasdaq: PRGO) has signed a merger agreement and completed the acquisition of Leeds, U.K.-based Rosemont Pharmaceuticals Ltd. for approximately £180 million or $283 million in cash. Read More

Perrigo (Nasdaq: PRGO) has received approval from the U.S. Food and Drug Administration for its New Drug Application for "testosterone gel 1%," which is comparable to AbbVie’s AndroGel 1% brand. Read More

Perrigo has signed a definitive agreement to acquire Velcera Inc. — an OTC pet health-products company in Yardley, Pa. — for $160 million in cash, with the acquisition expected to close this year. Read More

Smokers huddled out in the cold today may take heart with news out of Allegan that Perrigo (Nasdaq: PRGO) has launched a generic over-the-counter nicotine polacrilex mini lozenge — which it says is comparable to GlaxoSmithKline’s Nicorette. Read More

Allegan-based Perrigo Co. (Nasdaq: PRGO) has announced its infant formula division, Perrigo Nutritionals — the world's largest supplier of store brand infant formula — has FDA clearance to make three new infant formula products. Read More

Allegan pharmaceutical manufacturer Perrigo (Nasdaq: PRGO) has announced it has signed a definitive merger agreement and completed full acquisition of Cobrek Pharmaceuticals Inc., a privately-held, Chicago based drug development company, for approximately $45 million on a cash free and debt-free basis. Read More

Perrigo has announced that its partner, Cobrek Pharmaceuticals Inc., has received final approval from the U.S. Food and Drug Administration for its generic equivalent to Luxiq, a foam treatment for scalp psoriasis, with Perrigo now set to begin commercial shipments of it in mid January. Read More